UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2124-2130

2008

Volltextzugriff (PDF)

Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2754-2762

2005

Volltextzugriff (PDF)

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

European journal of nuclear medicine and molecular imaging, 2009-08, Vol.36 (8), p.1265-1272

2009

Volltextzugriff (PDF)

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

European Journal of Nuclear Medicine, 2001-09, Vol.28 (9), p.1319-1325

2001

Volltextzugriff (PDF)

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

European Journal of Nuclear Medicine, 2001-09, Vol.28 (9), p.1421-1429

2001

Volltextzugriff (PDF)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

European journal of nuclear medicine and molecular imaging, 2016-09, Vol.43 (10), p.1802

2016

Volltextzugriff (PDF)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

European journal of nuclear medicine and molecular imaging, 2016-03, Vol.43 (3), p.453

2016

Volltextzugriff (PDF)

Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

European journal of nuclear medicine and molecular imaging, 2007-11, Vol.34 (11), p.1854-1860

2007

Volltextzugriff (PDF)

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

European journal of nuclear medicine and molecular imaging, 2003, Vol.30 (1), p.9-15

2003

Volltextzugriff (PDF)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

European journal of nuclear medicine and molecular imaging, 2009-07, Vol.36 (7), p.1138-1146

2009

Volltextzugriff (PDF)

Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma

The Journal of nuclear medicine (1978), 2006-10, Vol.47 (10), p.1599-1606

2006

Volltextzugriff (PDF)

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

The Journal of nuclear medicine (1978), 2005-01, Vol.46 Suppl 1, p.83S

2005

Volltextzugriff (PDF)

Phase I study of peptide receptor radionuclide therapy with [ 111In-DTPA 0]octreotide: The rotterdam experience

Seminars in nuclear medicine, 2002-04, Vol.32 (2), p.110-122

2002

Volltextzugriff (PDF)

Nephrotoxicity after PRRT with super(177)Lu-DOTA-octreotate

European journal of nuclear medicine and molecular imaging, 2016-09, Vol.43 (10), p.1802-1811

2016

Volltextzugriff (PDF)

Nephrotoxicity after PRRT with ^sup 177^Lu-DOTA-octreotate

European journal of nuclear medicine and molecular imaging, 2016-09, Vol.43 (10), p.1802

2016

Volltextzugriff (PDF)

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

European journal of nuclear medicine and molecular imaging, 2016-03, Vol.43 (3), p.453-463

2016

Volltextzugriff (PDF)

Subacute haematotoxicity after PRRT with ^sup 177^Lu-DOTA-octreotate: prognostic factors, incidence and course

European journal of nuclear medicine and molecular imaging, 2016-03, Vol.43 (3), p.453

2016

Volltextzugriff (PDF)

Subacute haematotoxicity after PRRT with super(177)Lu-DOTA-octreotate: prognostic factors, incidence and course

European journal of nuclear medicine and molecular imaging, 2016-03, Vol.43 (3), p.453-463

2016

Volltextzugriff (PDF)

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

European journal of nuclear medicine and molecular imaging, 2016, Vol.43 (10), p.1802-1811

2016

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma

The Journal of nuclear medicine (1978), 2005-01, Vol.46 (1 suppl), p.107S-14S

2005

Volltextzugriff (PDF)

Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size

The Journal of nuclear medicine (1978), 2001-12, Vol.42 (12), p.1841-1846

2001

Volltextzugriff (PDF)

Lung clearance of intratracheally instilled 99m Tc‐tobramycin using pulmonary surfactant as vehicle

British journal of pharmacology, 2009-01, Vol.126 (5), p.1091-1096

2009

Volltextzugriff (PDF)

Receptor Scintigraphy with a Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals

The Journal of nuclear medicine (1978), 1990-09, Vol.31 (9), p.1501-1509

1990

Volltextzugriff (PDF)

In Vivo Use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism, and Binding to Somatostatin Receptor-Positive Tumors in Man

The Journal of nuclear medicine (1978), 1991-06, Vol.32 (6), p.1184-1189

1991

Volltextzugriff (PDF)

Comparison of 111In-DOTA-Tyr3-Octreotide and 111In-DTPA-Octreotide in the Same Patients: Biodistribution, Kinetics, Organ and Tumor Uptake

The Journal of nuclear medicine (1978), 1999-05, Vol.40 (5), p.762-767

1999

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Englisch
(82)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Humans
(49)
Life Sciences & Biomedicine
(48)
Male
(43)
Female
(35)
Middle Aged
(30)
Aged
(22)
Adult
(19)
Octreotide - Analogs & Derivatives
(19)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Radionuclide Imaging
(16)
Radiology, Nuclear Medicine & Medical Imaging
(15)
Infectious Diseases
(13)
Animals
(12)
Immunology
(12)
Radiopharmaceuticals - Therapeutic Use
(12)
Hiv
(11)
Octreotide - Therapeutic Use
(11)
Cohort Studies
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

Phase I study of peptide receptor radionuclide therapy with [ 111In-DTPA 0]octreotide: The rotterdam experience

Nephrotoxicity after PRRT with super(177)Lu-DOTA-octreotate

Nephrotoxicity after PRRT with ^sup 177^Lu-DOTA-octreotate

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

Subacute haematotoxicity after PRRT with ^sup 177^Lu-DOTA-octreotate: prognostic factors, incidence and course

Subacute haematotoxicity after PRRT with super(177)Lu-DOTA-octreotate: prognostic factors, incidence and course

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma

Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size

Lung clearance of intratracheally instilled 99m Tc‐tobramycin using pulmonary surfactant as vehicle

Receptor Scintigraphy with a Radioiodinated Somatostatin Analogue: Radiolabeling, Purification, Biologic Activity, and In Vivo Application in Animals

In Vivo Use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism, and Binding to Somatostatin Receptor-Positive Tumors in Man

Comparison of 111In-DOTA-Tyr3-Octreotide and 111In-DTPA-Octreotide in the Same Patients: Biodistribution, Kinetics, Organ and Tumor Uptake

Suchergebnisse filtern